CCA
SNDX icon

Cross Creek Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Cross Creek Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,649
Closed -$51K – 12
2021
Q4 		$51K Buy
+2,649
New +$48.9K 0.04% 9

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Cross Creek Advisors's SNDX Position: Q1 2022 in Review

Cross Creek Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2022, closing a stake of 2,649 shares — an estimated $51K sold.

Cross Creek Advisors first reported a position in SNDX in Q4 2021 and held it in 1 quarter. The position peaked at $51K in Q4 2021. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Cross Creek Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cross Creek Advisors sold 2,649 Syndax Pharmaceuticals shares in Q1 2022, an estimated $51K.
  • Cross Creek Advisors first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Cross Creek Advisors's Syndax Pharmaceuticals position peaked at $51K in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Cross Creek Advisors's 13F filing for Q1 2022, filed 12 May 2022.